When did CATALYST PHARMACEUTICALS INC (CPRX) report earnings last quarter?
CATALYST PHARMACEUTICALS INC (CPRX) last reported earnings on 2/25/2026.
CATALYST PHARMACEUTICALS INC (CPRX) Earnings History & Surprises
NASDAQ:CPRX • US14888U1016
Current stock price
25.175 USD
+0.23 (+0.94%)
Last:
CPRX Earnings overview
Past quarterly earnings results for CATALYST PHARMACEUTICALS INC (CPRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.46
- Revenue Estimate
- 150.18M
Last Reported
Most Recent- Release Date
- Feb 25, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.41
- EPS Surprise
- 19.63%
- Revenue Surprise
- 5.34%
Beat Rate
Last 8 Quarters 88%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.41 | 0.34 | 19.63% | -6.82% | 152.613M | 144.87M | 5.34% | 7.61% |
| Q3 2025 | 0.42 | 0.34 | 24.03% | 20.00% | 148.392M | 139.54M | 6.34% | 15.31% |
| Q2 2025 | 0.41 | 0.39 | 4.13% | 24.24% | 146.563M | 143.42M | 2.19% | 19.44% |
| Q1 2025 | 0.45 | 0.35 | 29.76% | 136.84% | 141.421M | 134.13M | 5.44% | 43.56% |
| Q4 2024 | 0.44 | 0.35 | 27.41% | 41.94% | 141.82M | 136.88M | 3.61% | 28.26% |
| Q3 2024 | 0.35 | 0.31 | 12.87% | 220.69% | 128.695M | 125.89M | 2.23% | 25.33% |
| Q2 2024 | 0.33 | 0.27 | 22.55% | -37.74% | 122.71M | 114.1M | 7.55% | 23.23% |
| Q1 2024 | 0.19 | 0.20 | -2.98% | -26.92% | 98.509M | 100.09M | -1.58% | 15.40% |
| Q4 2023 | 0.31 | 0.27 | 14.69% | 40.91% | 110.568M | 108.04M | 2.34% | 81.86% |
| Q3 2023 | -0.29 | -0.29 | 0.24% | -245.00% | 102.688M | 102.38M | 0.30% | 79.52% |
| Q2 2023 | 0.53 | 0.36 | 45.96% | 165.00% | 99.582M | 93.54M | 6.46% | 87.54% |
| Q1 2023 | 0.26 | 0.33 | -20.84% | 116.67% | 85.366M | 83.249M | 2.54% | 98.06% |
| Q4 2022 | 0.22 | 0.22 | 1.74% | 144.44% | 60.8M | 59.252M | 2.61% | 58.75% |
| Q3 2022 | 0.20 | 0.19 | 3.20% | 100.00% | 57.2M | 54.696M | 4.58% | 58.89% |
| Q2 2022 | 0.20 | 0.17 | 15.34% | 81.82% | 53.1M | 50.197M | 5.78% | 45.88% |
| Q1 2022 | 0.12 | 0.14 | -13.49% | 71.43% | 43.1M | 43.61M | -1.17% | 42.72% |
| Q4 2021 | 0.09 | 0.12 | -23.94% | -18.18% | 38.3M | 38.955M | -1.68% | 23.55% |
| Q3 2021 | 0.10 | 0.11 | -5.73% | -9.09% | 36M | 35.28M | 2.04% | 22.87% |
| Q2 2021 | 0.11 | 0.10 | 12.34% | 22.22% | 36.4M | 32.138M | 13.26% | 22.97% |
| Q1 2021 | 0.07 | 0.09 | -23.75% | -30.00% | 30.2M | 32.742M | -7.76% | 3.78% |
| Q4 2020 | 0.11 | 0.09 | 17.22% | - | 31M | 30.957M | 0.14% | - |
| Q3 2020 | 0.11 | 0.10 | 12.34% | - | 29.3M | 32.124M | -8.79% | - |
| Q2 2020 | 0.09 | 0.09 | 3.81% | - | 29.6M | 30.074M | -1.58% | - |
| Q1 2020 | 0.10 | 0.09 | 13.12% | - | 29.1M | 32.092M | -9.32% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
19.39%
Max EPS beat (4)
29.76%
Min EPS beat (4)
4.13%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
4.83%
Max Revenue beat (4)
6.34%
Min Revenue beat (4)
2.19%
Analysis
In the last 4 quarters, CPRX has consistently beaten EPS estimates in all releases
CPRX has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, CPRX has beaten the EPS estimates by 19.4% on average.
In the last 4 quarters, CPRX has beaten the revenue estimates by 4.8% on average.
Related analysis
CATALYST PHARMACEUTICALS INC / CPRX Earnings FAQ
Can you provide information on whether CATALYST PHARMACEUTICALS INC beat earnings estimates in the last quarter?
CATALYST PHARMACEUTICALS INC (CPRX) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does CPRX stock beat earnings estimates?
In the last 4 quarters, CATALYST PHARMACEUTICALS INC (CPRX) has beaten EPS estimates in 4 out of 4 releases.